2 years ago

Harness Therapeutics Secures £4 Million Funding for Huntington's Disease Program

  • Harness Therapeutics, a UK-based biotech company focused on physiological protein upregulation, raised an additional £4 million in funding, bringing the total to £17.6 million

  • The round was led by SV Health Investors, with participation from Takeda Ventures and The Dementia Discovery Fund (DDF)

  • The funds will be used to advance the company's lead program targeting FAN1 nuclease in Huntington's Disease towards clinical trials

  • Harness Therapeutics was initially founded by Takeda Ventures and The Dementia Discovery Fund in 2020, later joined by Epidarex Capital in 2022

  • The company has developed a unique approach to upregulating protein expression using oligonucleotide-based drugs and aims to leverage its expertise in RNA biology for therapeutic development in neurodegenerative diseases.

      • ProblemHealthcare

      "Huntington's Disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. There is no cure for Huntington’s Disease, and current treatments only manage the symptoms."

      Solution

      "Harness Therapeutics is developing a new treatment for Huntington's Disease that uses oligonucleotide-based drugs to upregulate protein expression. This approach could potentially slow down or even stop the progression of the disease."

      Covered on